What is the relative risk reduction in VTE for patients receiving rivaroxaban compared to warfarin with a BMI of 40 kg/m2?

What is the relative risk reduction in VTE for patients receiving rivaroxaban compared to warfarin with a BMI of 40 kg/m2?

• A. 20%
• B. 44.3%
• C. 3.1%
• D. 57%

Answer: (B)

The relative risk reduction in venous thromboembolism (VTE) for patients receiving rivaroxaban compared to warfarin emphasizes the efficacy of rivaroxaban as an anticoagulant. In clinical studies, rivaroxaban has demonstrated a significant decrease in the incidence of VTE, particularly in patients with certain risk factors, including obesity, which is represented by a BMI of 40 kg/m² in this case.

Rivaroxaban's mechanism of action, which involves the direct inhibition of factor Xa, allows for more predictable pharmacodynamics compared to warfarin, leading to less variability in dosing and better adherence profiles. The reported relative risk reduction of 44.3% indicates a substantial benefit for patients using rivaroxaban, reinforcing its role as a preferred option for managing patients at risk for VTE.

This figure reflects the outcome of pooled analyses from clinical trials that have favored rivaroxaban over warfarin, especially among populations where standard VTE prophylaxis was critically needed. It is essential for clinicians to understand these statistics as they influence therapeutic decisions in the management of patients with high body mass indexes who may be at greater risk for thromboembolic events.